U.S. healthcare regulators put their highest-risk Class I label on Medtronic's Paradigm insulin infusion pump recall.
Medtronic Canada said last month that it received 2 reports on its Paradigm and Polyfin infusion devices, concerning the over- and under-delivery of insulin therapy.
Medtronic informed patients, healthcare providers and pharmacies in Canada of the potential problem, to explain how to avoid it, according to the Brampton Guardian.
In an update issued July 12, the FDA said that the Paradigm pumps were recalled "because of a potential safety issue that can occur if insulin or other fluids come in contact with the inside of the tubing connector."
"If this occurs it can temporarily block the vents that allow the pump to properly prime," according to the FDA notice. "This can result in too much or too little insulin being delivered resulting in hypoglycemia or hyperglycemia which can be severe and lead to serious illness."
The FDA labels as Class I CareFusion's recall of its Avea ventilators over a possibly fatal...
Small medtech companies are finding value in outsourcing their research & development functions,...
VertiFlex says it won pre-market approval from the FDA for its Superion interspinous spacer.
China is investigating a former top healthcare official on suspicion of bribery.
Medtronic is reportedly looking to grow its presence in China with lower-cost devices, as well as...